^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Gastrointestinal Stromal Tumor

3d
Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib. (PubMed, BMC Med)
Our results demonstrate that dapagliflozin not only enhances the antitumor efficacy of sunitinib against renal cell carcinoma but also alleviates sunitinib-induced cardiac toxicity in mice via modulation of the AMPKα-PPARα axis.
Journal
|
PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
sunitinib
3d
Transanal minimally invasive surgery for rectal gastrointestinal stromal tumor using articulated forceps after neoadjuvant chemotherapy with imatinib mesylate. (PubMed, Int Cancer Conf J)
Notably, this is the first report of ArtiSential articulated forceps utilized in TAMIS, demonstrating their innovative potential in enhancing surgical precision and outcomes in challenging pelvic procedures. The online version contains supplementary material available at 10.1007/s13691-025-00786-7.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • ANO1 (Anoctamin 1)
|
KIT mutation
|
imatinib
7d
Small bowel GISTs: clinicopathological patterns and the role of inflammatory markers. (PubMed, Rom J Morphol Embryol)
Although inflammatory markers showed limited overall correlations, the PLR-PNI relationship and reduced PNI in necrotic tumors suggest that inflammation and nutritional decline may reflect tumor aggressiveness in small bowel GISTs. Larger studies are needed to confirm these findings.
Retrospective data • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • ANO1 (Anoctamin 1)
8d
Primary extra-gastrointestinal stromal tumor of the gallbladder: A case report. (PubMed, World J Gastroenterol)
Primary gallbladder EGISTs are exceedingly rare, with insidious onset and nonspecific clinical manifestations. Histopathological examination combined with immunohistochemistry remains the cornerstone of definitive diagnosis.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule) • ANO1 (Anoctamin 1)
|
imatinib
9d
reGISTTry: A Comprehensive, Multinational GIST Registry (clinicaltrials.gov)
P=N/A, N=1000, Not yet recruiting, Universität Duisburg-Essen
New trial
9d
Disparities in management guidelines for gastrointestinal stromal tumors: A comparison of recommendations from the Chinese Society of Clinical Oncology, National Comprehensive Cancer Network, and European Society for Medical Oncology. (PubMed, Cancer)
The advent of targeted therapy, notably the first tyrosine kinase inhibitor (TKI) imatinib, has revolutionized the treatment landscape for GISTs...This commentary highlights discrepancies in the recommendations for managing GISTs as outlined in these major guidelines. Based on emerging new evidence from recent studies, the authors propose recommendations to be considered for inclusion in future guideline updates to optimize management strategies and ultimately improve the outcomes of patients with GISTs.
Clinical • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
|
KIT mutation
|
imatinib
10d
Germ cell immunoprofile and KIT exon 17 mutation guide rectification of seminoma misclassified as epithelioid gastrointestinal stromal tumor: A case report. (PubMed, Biomed Rep)
Definitive diagnosis of seminoma was established through expanded immunohistochemistry (OCT4+/SALL4+/PLAP+/D2-40+) and molecular confirmation of the characteristic KIT p.D816Y mutation, which concurrently explains the observed imatinib resistance. In conclusion, the findings of the present study highlighted the imperative of integrating morphology, immunohistochemistry and context-specific molecular profiling to avoid diagnostic in CD117-positive tumors.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • ALPP (Alkaline Phosphatase, Placental) • POU5F1 (POU Class 5 Homeobox 1) • SALL4 (Spalt Like Transcription Factor 4)
|
KIT mutation
|
imatinib
11d
Comprehensive Molecular Screening by Next Generation Sequencing of Gastrointestinal Stromal Tumors (GISTs): In Silico Analysis and Classification of Rare KIT Exon 11 Mutations. (PubMed, Cancer Med)
Our findings highlight the clinical relevance of integrating NGS into routine GIST management, particularly for the identification and interpretation of rare genetic variants. The study underscores the importance of data sharing and collective variant annotation to support accurate molecular classification, prognostic assessment, and therapeutic decision-making for individual patients.
Retrospective data • Journal • Next-generation sequencing
|
BRAF (B-raf proto-oncogene) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
|
BRAF mutation • KIT mutation • PDGFRA mutation
|
imatinib
13d
INTEREST: Ripretinib (QINLOCK®) According to Current SmPC (clinicaltrials.gov)
P=N/A, N=10, Completed, iOMEDICO AG | Recruiting --> Completed | N=100 --> 10 | Trial completion date: Nov 2027 --> Sep 2025 | Trial primary completion date: Sep 2027 --> Aug 2025
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
Qinlock (ripretinib)
14d
GIST Trial 13-162: MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov)
P1/2, N=75, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
Trial completion date • Trial primary completion date
|
imatinib • Mektovi (binimetinib)
14d
Genomic Profile and Clinicopathological Analyses of Wild-Type Gastrointestinal Stromal Tumors. (PubMed, Mol Cancer Res)
Considering the rarity and heterogeneity of WT-GISTs, a regulatory detection procedure should be established for WT-GISTs, including NGS for qWT-GISTs, to identify the molecular mechanisms and potential therapeutic targets. Implications: WT-GISTs are heterogenous tumors which should be managed using different treatments and follow-up strategies.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • ARID1B (AT-Rich Interaction Domain 1B) • PLCG2 (Phospholipase C Gamma 2)